NHLBI Trial Choice Validates Cytori (CYTX) as Top Stem Cell Player - Roth Capital
Tweet Send to a Friend
Roth Capital affirms Cytori Therapeutics (Nasdaq: CYTX) at Buy with a target price of $10 following news that the Cardiovascular ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
